Scilex Holding Company (SCLX)의 가격은 얼마입니까?

Scilex Holding Company (SCLX)의 가격은 $5.61입니다.

Scilex Holding Company (SCLX)의 시가 총액은 무엇입니까?

Scilex Holding Company (SCLX)의 시가 총액은 $47.65M입니다.

Scilex Holding Company (SCLX) 수익

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

연도	수익	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

수익

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	수익	수익 차이	국가
Eli Lilly and Company LLY.US	$33.59B	-	US
Johnson & Johnson JNJ.US	$25.20B	-	US
AbbVie Inc. ABBV.US	$8.70B	-	US
Roche Holding AG RO.SW	$21.39B	-	CH
Merck & Co., Inc. MRK.US	$5.95B	-	US

회사

수익

수익 차이

국가